106 results
424B3
BTTX
Better Therapeutics Inc
10 Jan 24
Prospectus supplement
7:01am
, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
(i) Material Changes; Undisclosed Events, Liabilities
8-K
EX-10.1
BTTX
Better Therapeutics Inc
8 Jan 24
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
4:42pm
, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
(i) Material Changes; Undisclosed Events
424B3
BTTX
Better Therapeutics Inc
28 Dec 23
Prospectus supplement
9:23pm
as more patient data become available and are subject to confirmation, audit, and verification procedures that could result in material changes … additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final
8-K
EX-10.1
ce4hnej
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-10.2
qkoo7m2q kp0df87
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm
8-K
EX-10.1
zypd8gp 83
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm
8-K
EX-10.1
kznsl9t2 pmw
11 May 23
Entry into a Material Definitive Agreement
5:23pm